Publication at First Faculty of Medicine |
2018
Abstract
Authors describe mechanism of action of lipid-lowering drug named alirocumab. They bring an overview of a program of clinical trials - ODYSSEY that is fussed on patients with a familiar hypercholesterolemia and on patients with a high risk for cardiovascular events.